ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Travoprost

Also written as “Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)”, “Travoprost 0.004% / Timolol maleate 0.5%” and “Travoprost 0.004% ophthalmic solution”.

Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Glaucoma, Angle-Closure · Low Tension Glaucoma · Hydrophthalmos, led by 5 companies.

Drug pageTravoprost: every studyMany companies study it; this page follows only the 63 they lead. All 80 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 28, 200363 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alcon520 open or runningphase 4since May 28, 2003Jan 3, 2003none ahead
Glaukosits history only72 open or runningphase 4since Sep 28, 2011Sep 28, 2011none ahead
Ocular Therapeutixits history only20 open or runningphase 3since Sep 21, 2016Dec 4, 2014none ahead
Laboratorios Sophia S.A de C.V.its history only10 open or runningphase 1since May 23, 2019May 23, 2019none ahead
Viatrisits history only10 open or runningphase 4since Feb 16, 2009Feb 16, 2009none ahead

Also a collaborator on its studies: PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Alcon only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 36 studies since Jan 3, 2003.

  1. Oct 28, 2010Phase 4 study in GlaucomaNCT01230736 · 105 enrolled · Germany
  2. Feb 16, 2011Phase 2 study in Glaucoma, Open-AngleNCT01298687 · 67 enrolled
  3. Mar 30, 2011Phase 4 study in Glaucoma, Open-AngleNCT01327599 · 60 enrolled
  4. Apr 14, 2011Phase 4 study in GlaucomaNCT01336569 · 50 enrolled · United States
  5. Oct 12, 20112 phase 3 studies in Glaucoma, Open-AngleNCT01452009, NCT01453855
  6. Nov 1, 2011Phase 4 study in GlaucomaNCT01464424 · 84 enrolled
  7. Dec 14, 2011Phase 4 study in Glaucoma, Open-AngleNCT01493427 · 202 enrolled
  8. Jan 11, 20122 phase 4 studies in Glaucoma, Open-AngleNCT01510145, NCT01510132
  9. Jul 26, 2012Phase 3 study in HydrophthalmosNCT01652664 · 184 enrolled
  10. Aug 3, 2012Phase 1 study in GlaucomaNCT01658839 · 25 enrolled
  11. Aug 10, 2012Phase 4 study in GlaucomaNCT01664039 · 104 enrolled
  12. Sep 27, 2012Phase 4 study in GlaucomaNCT01696383
  13. Nov 21, 2013Phase 4 study in Low Tension GlaucomaNCT01995136 · 32 enrolled · Japan
  14. Dec 2, 2013Phase 4 study in Glaucoma, Open-AngleNCT02003391 · 157 enrolled

TargetBeta

PTGFR →read by rule
“Prostanoid FP receptor agonist”ChEMBL 37, by rule

Other programs on PTGFR

ProgramCompanyFurthest phaseStudies
AGN-193408AbbViephase 21

Studies

All 52 Alcon leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02003391Glaucoma, Open-Angle4CompletedMay 2015157
NCT01995136Low Tension Glaucoma · Japan4CompletedJun 201432
NCT01696383Glaucoma4WithdrawnFeb 20130
NCT01664039Glaucoma4CompletedJun 2014104
NCT01658839Glaucoma1CompletedJul 201325
NCT01652664Hydrophthalmos3CompletedMar 2014184
NCT01510145Glaucoma, Open-Angle4CompletedMay 2013191
NCT01510132Glaucoma, Open-Angle4WithdrawnJan 20120
NCT01493427Glaucoma, Open-Angle4CompletedFeb 2013202
NCT01464424Glaucoma4CompletedJun 201284
NCT01453855Glaucoma, Open-Angle3CompletedAug 20121,099
NCT01452009Glaucoma, Open-Angle3WithdrawnDec 20110
NCT01336569Glaucoma · United States4CompletedMar 201250
NCT01327599Glaucoma, Open-Angle4CompletedNov 201260
NCT01298687Glaucoma, Open-Angle2CompletedApr 201167
NCT01230736Glaucoma · Germany4CompletedFeb 2011105
NCT01114893Glaucoma, Open-Angle · United States2CompletedMay 201060
NCT00966940Glaucoma4CompletedMar 201051
NCT00928590Glaucoma, Open-Angle3CompletedNov 2010155
NCT00872651Glaucoma, Open-Angle · China3CompletedNov 2011242
NCT00848536Glaucoma, Open-Angle3CompletedJan 2010371
NCT00798759Glaucoma, Open-Angle4CompletedMay 2009236
NCT00767494Glaucoma · Belgium3TerminatedFeb 200917
NCT00767481Glaucoma · Mexico3TerminatedFeb 20096
NCT00763061Glaucoma · United States4CompletedApr 2008111
NCT00761319Glaucoma, Open-Angle3CompletedSep 2009705
NCT00762645Glaucoma, Angle-Closure4CompletedMay 200830
NCT00760539Glaucoma, Open-Angle · Japan3CompletedDec 200887
NCT00759239Glaucoma, Open-Angle · United Kingdom4CompletedJan 201136
NCT00758342Intraocular Pressure4TerminatedMar 200837
NCT00708422Glaucoma4CompletedAug 2009231
NCT00690794Glaucoma, Open-Angle3CompletedMay 2009726
NCT00672997Glaucoma, Open-Angle3CompletedDec 2008301
NCT00670033Ocular Hypertension2CompletedSep 2008158
NCT00527592Glaucoma, Open-Angle4CompletedAug 200854
NCT00527501Glaucoma, Open-Angle · United States2CompletedDec 2007136
NCT00519753Glaucoma · Germany4CompletedDec 2008522
NCT00508469Glaucoma, Open-Angle · Spain4CompletedJan 2010102
NCT00471380Glaucoma · Italy4CompletedOct 200846
NCT00471068Glaucoma, Open-Angle · Portugal4TerminatedAug 200846
NCT00468988Glaucoma · United States4CompletedJul 200730
NCT00465803Glaucoma, Open-Angle · United States3CompletedJan 200981
NCT00444665Glaucoma · United States4CompletedAug 2007750
NCT00333125Glaucoma3CompletedFeb 2007319
NCT00311389Glaucoma, Open-Angle · Belgium3CompletedSep 2004408
NCT00293800Glaucoma, Open-Angle3CompletedDec 2005173
NCT00293787Glaucoma, Open-Angle3CompletedAug 2005156
NCT00288951Glaucoma, Open-Angle3CompletedJun 2005690
NCT00061503Glaucoma · United States4CompletedMar 2004
NCT00051181Glaucoma, Angle-Closure · United States, Australia3CompletedJun 2003
NCT00051168Glaucoma, Open-Angle · United States3CompletedMar 2009502
NCT00051142Glaucoma, Open-Angle · United States3CompletedJun 2004

How it is read

Names in the registry

  • “Travoprost”, 6 entries
  • “Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)”, 5 entries
  • “Travoprost 0.004% / Timolol maleate 0.5%”, 2 entries
  • “Travoprost 0.004% ophthalmic solution”, 2 entries
  • “Travoprost ophthalmic solution, 0.004%”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.